Can a Heart Valve That Grows With a Child Spare Repeat Surgeries?
The FDA has approved Autus, a synthetic pulmonary heart valve that can spare children some of the repeat open-heart surgeries a fixed valve requires. It's sewn in once during open-heart surgery, and as the child grows, a cardiologist can thread a balloon catheter up to it and widen it without opening the chest. It tops out around an adult valve size, so it carries a child through the growing years, and how well it holds up over many years is still being tracked.
On October 1, 2026, the FDA cleared the Autus Size-Adjustable Valve for children with congenital pulmonary valve disease. It is the first pediatric heart valve designed to be enlarged after it is implanted, and the first US-approved heart valve with leaflets made of synthetic polymer. The valve is sewn in during open-heart surgery at a diameter sized to the child. The approved range spans roughly 13 mm at implant to about 22 mm after expansion, which covers the span from a toddler-sized pulmonary valve to an adult one.
Why a growing valve matters here
The main problem Autus is trying to solve is that children outgrow their valves. A valve replaced in a two-year-old was never going to fit a twelve-year-old's heart. So the standard path for a child born with tetralogy of Fallot, pulmonary atresia, or truncus arteriosus has been to accept a cycle of open-heart redos: implant a fixed valve, let the child grow out of it, open the chest, swap it, and do it again.
The published numbers on fixed valves show how fast that cycle runs. At five years, around 90 to 95 percent of children have not needed another intervention. By ten years, that drops to roughly half to two thirds. Children under 18 face about five times the reintervention risk of adults getting the same valve.
How the valve is widened without surgery
Autus is implanted the first time through a standard open-heart operation on bypass. What changes is what happens afterward. Instead of growing out of the valve and needing another sternotomy, the child can go to the cath lab. The cardiologist threads a catheter with a balloon on its tip up through a vein in the groin to the valve, inflates it inside the frame, and the frame expands. The synthetic leaflets are designed to stay competent at the new diameter.
The approval rests on two separate studies. An earlier US early feasibility study in 11 children, published in 2025, reported no deaths, no device-related adverse events, no thrombus, and no endocarditis at one year. The pivotal study the FDA used for approval was larger but shorter: across twelve US centers, 62 children received the valve, with the primary endpoint at six months. No child died, had a stroke, or had a clot needing treatment, and all were free of device-related complications at 30 days. Two children who began to outgrow their valve were taken to the cath lab and re-expanded without surgery, which is the core promise of the device, demonstrated in patients.
What the trial can't show yet
Pediatric valves tend to look good at one year and start to deteriorate between years five and ten, which is exactly the window the pivotal data can't yet speak to. Three of the 62 children had frame fractures, and two had reduced leaflet motion. Those are the early warning signs that will matter when post-approval studies hit five and ten years.
The broader literature on growth-accommodating valves is also sobering. Earlier expandable designs built on bovine jugular vein tissue did allow serial balloon dilations and lower gradients, but perivalvular leaks and structural deterioration still forced surgical revision in a meaningful share of children, and bovine jugular vein valves carry the highest endocarditis risk of the pulmonary valve options. Autus uses synthetic leaflets, which is one reason to hope it does better on tissue degeneration and endocarditis, though that hope hasn't been tested over the long term yet.
Where Autus fits among the other options
| Valve type | How reinterventions happen | Durability signal in children |
|---|---|---|
| Autus size-adjustable synthetic valve | Balloon widening in the cath lab, up to about 22 mm | No long-term data yet; 62 children followed short-term |
| Surgical bioprosthetic valve | Another open-heart replacement, or a catheter valve placed inside it | Holds up for about five years, then reinterventions climb steeply |
| Cryopreserved pulmonary homograft | Open-heart replacement; does not grow | More durable than bioprosthetic valves in tetralogy of Fallot |
| Melody transcatheter valve (bovine jugular vein) | Placed by catheter inside an existing conduit or valve | Repeat interventions common in small children by 10 years; highest endocarditis risk |
Each option is a trade. Homografts last longer than most options but do not grow, so a small child gets a conduit they will outgrow. Melody is already catheter-based but is placed inside a surgical conduit that had to go in first, and it carries a higher endocarditis signal. Autus is the first device whose first implant is sized to a small child and whose later enlargements do not require opening the chest.
Who this changes care for, and who it does not
If your child is facing pulmonary valve replacement, especially a young or small child likely to need multiple reoperations, Autus is now a real option to raise with your pediatric cardiac team. The question to ask is specific: is my child's anatomy and diagnosis within the label, and does your center implant Autus? The twelve pivotal-trial centers have the most experience with it so far.
Autus doesn't change the plan for children whose problem is on the aortic side or children whose anatomy falls outside the approved indication. It does not remove the need for lifelong cardiology follow-up. And it does not end heart surgery for congenital heart disease; it is expected to postpone, not eliminate, a later surgical revision, because the device tops out around an adult pulmonary valve size and its long-term durability is unknown.
The judgment
The right way to think about Autus is as a bridge through childhood. It trades some open-heart redos for cath lab visits during the years when children grow the fastest, with a safety profile strong enough for the FDA to approve it on 62 patients and six months of primary data. What it has not yet shown is how long the synthetic leaflets and the frame will hold up over the decade when previous pediatric valves have started to fail. Five- and ten-year post-approval data on frame fracture, leaflet failure, endocarditis, and how often the valve gets re-expanded will show whether it lasts longer than the valves it's meant to replace. For a family facing a childhood of sternotomies today, Autus is worth asking about before those results are in.